Access to Outpatient Longitudinal Drug Utilization Data

The Department of Health and Human Services' Food and Drug Administration (FDA), specifically the Center for Drug Evaluation and Research, is seeking a contractor to provide comprehensive access to outpatient longitudinal drug utilization data. The agency requires real-time, unlimited, multi-user desktop access to commercially available data that includes national and geographical prescription and patient counts over time. Key contract requirements include providing prescription and medical claims data, patient-level demographic information, and the ability to analyze drug exposure duration and concomitant use patterns. The contractor must maintain HIPAA compliance, offer large dataset download capabilities, and provide 200 annual ad-hoc programming hours with technical support during business hours. Responses to the Sources Sought notice are due by January 23, 2025, at 10 A.M. EST, with submissions limited to 10 pages and to be emailed to Telisha.Wilson@fda.hhs.gov.

The procurement is specifically targeting small businesses, including HUBZone, service-disabled veteran-owned, 8(a), veteran-owned, woman-owned, and small disadvantaged businesses. The contract will be an indefinite delivery indefinite quantity (IDIQ) type with a five-year ordering period under the NAICS code 541519 for Other Computer Related Services. The contractor must provide a minimum of 10 years of historical data, with weekly data deliveries having no more than an 8-day lag and monthly data with a 30-day maximum lag. Specific performance requirements include 24-hour turnaround for urgent clearance requests, 48-hour advance notice of planned system downtime, and participation in kick-off and annual meetings. While no specific award value is mentioned, the comprehensive data access and extensive reporting requirements suggest a significant engagement for the selected vendor. The government will use the responses to determine the most appropriate acquisition method, potentially including set-asides for qualifying small businesses.